BOSULIF Film-coated Tablet
Bosutinib
100 mg
PFIZER MANUFACTURING DEUTSCHLAND GmbH
| Pack size | 28's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 94.13 AED |
Indications
BOSULIF Film-coated Tablet is used for:
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Bosutinib :
Mechanism of Action
Bosutinib is a tyrosine kinase inhibitor. Although it is able to inhibit several tyrosine kinases such as Src, Lyn, and Hck, which are members of the Src-family of kinases, its primary target is the Bcr-Abl kinase. The Bcr-Abl gene is a chimeric oncogene created from the fusion of the breakpoint-cluster (Bcr) gene and Abelson (Abl) tyrosine gene. This chromosomal abnormality results in the formation of what is commonly known as the Philadelphia chromosome or Philadelphia translocation. The Bcr-Abl gene expresses a particular kinase that promotes the progression of CML. A decrease in the growth and size of the CML tumour has been observed following administration of bosutinib. Bosutinib did not inhibit the T315I and V299L mutant cells.
Note
BOSULIF 100 mg Film-coated Tablet manufactured by PFIZER MANUFACTURING DEUTSCHLAND GmbH. Its generic name is Bosutinib. BOSULIF is availble in Saudi Arabia.
Farmaco SA drug index information on BOSULIF Film-coated Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.